#USA #New Orleans #Nordic Pharma #LACRIFILL #SEVER Life Sciences

Nordic Pharma Introduces LACRIFILL® at the American Academy of Ophthalmology

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., is set to unveil its groundbreaking product, LACRIFILL® Canalicular Gel, at the upcoming American Academy of Ophthalmology (AAO) conference in New Orleans, Louisiana, running from October 9 to 12, 2026. This innovative gel is designed for ocular surface control and promises significant benefits for patients who have undergone cataract or refractive surgeries.

At the AAO 2026 conference, Nordic Pharma will present the latest findings regarding patient experiences using LACRIFILL®. Over 2,200 eye care practices across the United States currently utilize this canalicular gel, primarily aimed at patients recovering from surgery and dealing with dry eye symptoms.

To date, the treatment has benefitted over 130,000 patients, with remarkable results highlighted in a recent survey. A staggering 96% of cataract surgery patients reported improved comfort from using LACRIFILL®, and 91% of all participants in the study expressed that it enhanced their overall eye experience.

Dr. Jai G. Parekh, the Chief Commercial Officer at Nordic Pharma, stated, "The AAO event is an exceptional platform to discuss advancements in ophthalmology. We are eager to showcase data that supports the use of LACRIFILL® gel, which has been linked to higher comfort levels and more stable vision for postoperative applications and dry eye treatment. Furthermore, patients reported a reduced reliance on both prescription and over-the-counter eye drops."

Dr. David Szynkarski from the Mann Eye Institute in Houston, Texas, emphasized the importance of controlling ocular surfaces post-surgery, citing that 83% of patients treated with LACRIFILL® reported reduced discomfort. He noted, "This relief is significant, especially considering that LACRIFILL® can be used safely for up to six months, maintaining these benefits long after treatment."

At the conference, attendees will have the opportunity to see healthcare professionals administering the LACRIFILL® gel on-site, as Nordic Pharma's booth (#3136) will feature live demonstrations on Saturday, October 10, and Sunday, October 11, from 10:00 AM to 4:00 PM. Moreover, visitors will have the chance to place orders directly at the booth.

For further details and ordering inquiries regarding LACRIFILL®, participants can visit lacrifill.com.

About SEVER Life Sciences B.V.

SEVER Life Sciences B.V. is a global specialty pharmaceutical holding company based in the Netherlands, committed to improving the quality of life for individuals worldwide. The company encompasses three diverse but complementary businesses, providing a wide variety of products, pharmaceutical development services, and administration technologies.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. partners with established global biopharmaceutical companies, leveraging its expertise in the marketing of healthcare products and sterile manufacturing. This enables the company to provide innovative solutions in the ophthalmology sector while maintaining a focus on improving patient outcomes.

Conclusion

Nordic Pharma's participation at AAO 2026 isn't merely about demonstrating a product; it's about sharing a vision for enhanced patient care through innovative therapies like LACRIFILL®. The data presented will undoubtedly spark important discussions on advancing practices within ophthalmology, ultimately benefiting patients experiencing the side effects of ocular procedures.